^
    No biomarker
    Marginal Zone Lymphoma
    rituximab + lenalidomide
    Sensitive: A1 - Approval
    FDA - 5 days - (New A1)
    TNFAIP3 mutation
    Marginal Zone Lymphoma
    zanubrutinib
    Sensitive: C3 – Early Trials
    EHA 2022 - 2 weeks - (New C3)
    MYD88 mutation
    Marginal Zone Lymphoma
    zanubrutinib
    Sensitive: C3 – Early Trials
    EHA 2022 - 2 weeks - (New C3)
    No biomarker
    Marginal Zone Lymphoma
    zanubrutinib
    Sensitive: A1 - Approval
    No biomarker
    Marginal Zone Lymphoma
    umbralisib
    Sensitive: A1 - Approval
    No biomarker
    Marginal Zone Lymphoma
    ibrutinib
    Sensitive: A1 - Approval
    No biomarker
    Marginal Zone Lymphoma
    R-CVP
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    R-CHOP
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    rituximab
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    axicabtagene ciloleucel
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    obinutuzumab
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    idelalisib
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    duvelisib
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    copanlisib
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    cyclophosphamide
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    chlorambucil
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    ibritumomab tiuxetan
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    G-CHOP
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    lisocabtagene maraleucel
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    tisagenlecleucel-T
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    O-CVP
    Sensitive: A2 - Guideline
    No biomarker
    Marginal Zone Lymphoma
    INCB50465
    Sensitive: B - Late Trials
    MYD88 mutation
    Marginal Zone Lymphoma
    ibrutinib
    Sensitive: C3 – Early Trials
    CARD11 mutation
    Marginal Zone Lymphoma
    ibrutinib
    Resistant: C3 – Early Trials
    KMT2D mutation
    Marginal Zone Lymphoma
    ibrutinib
    Resistant: C3 – Early Trials
    MYD88 L265P
    Marginal Zone Lymphoma
    ibrutinib
    Sensitive: C3 – Early Trials
    TNFAIP3 mutation
    Marginal Zone Lymphoma
    ibrutinib
    Sensitive: C3 – Early Trials
    CD5 positive
    Marginal Zone Lymphoma
    rituximab
    Resistant: C3 – Early Trials
    LDH elevation
    Marginal Zone Lymphoma
    ViPOR
    Sensitive: C3 – Early Trials
    TP53 mutation + MET amplification + PD-L1 overexpression
    Marginal Zone Lymphoma
    sintilimab
    Sensitive: C4 – Case Studies
    NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation
    Marginal Zone Lymphoma
    rituximab
    Sensitive: C4 – Case Studies
    BIRC3-MALT1 fusion
    Marginal Zone Lymphoma
    R-CHOP
    Sensitive: C4 – Case Studies
    CD20 expression + PAX5 expression + BCL2 expression
    Marginal Zone Lymphoma
    rituximab
    Sensitive: C4 – Case Studies